The Potential Role of Salivary NT-proBNP in Heart Failure

被引:1
|
作者
Rammos, Aidonis [1 ,2 ]
Bechlioulis, Aris [1 ,2 ]
Kalogeras, Petros [1 ,2 ]
Watson, Chris J. [3 ,4 ]
Salvo, Pietro [5 ]
Lomonaco, Tommaso [6 ]
Kardakari, Olga [1 ,2 ]
Tripoliti, Evanthia E. [7 ]
Goletsis, Yorgos [7 ,8 ]
Fotiadis, Dimitris I. [7 ,8 ,9 ]
Katsouras, Christos S. [1 ,2 ]
Michalis, Lampros K. [1 ,2 ]
Naka, Katerina K. [1 ,2 ]
机构
[1] Univ Ioannina, Fac Med, Sch Hlth Sci, Dept Cardiol 2, Ioannina 45500, Greece
[2] Univ Hosp Ioannina, Ioannina 45110, Greece
[3] Queens Univ Belfast, Wellcome Wolfson Inst Expt Med, Belfast BT9 7BL, North Ireland
[4] Univ Coll Dublin, UCD Conway Inst, Sch Med, Dublin, Ireland
[5] Italian Natl Res Council, Inst Clin Physiol, Via G Moruzzi 1, I-56124 Pisa, Italy
[6] Univ Pisa, Dept Chem & Ind Chem, I-56124 Pisa, Italy
[7] FORTH, Inst Mol Biol & Biotechnol IMBB, Dept Biomed Res, Ioannina 45110, Greece
[8] Univ Ioannina, Dept Econ, Ioannina 45110, Greece
[9] Univ Ioannina, Unit Med Technol & Intelligent Informat Syst, Ioannina 45110, Greece
来源
LIFE-BASEL | 2023年 / 13卷 / 09期
基金
欧盟地平线“2020”;
关键词
acute heart failure; chronic heart failure; heart failure diagnosis; saliva NT-proBNP; salivary biomarkers; ACUTE MYOCARDIAL-INFARCTION; NATRIURETIC PEPTIDE; DIAGNOSIS; BIOMARKERS; FURIN; RISK;
D O I
10.3390/life13091818
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Serum natriuretic peptides (NPs) have an established role in heart failure (HF) diagnosis. Saliva NT-proBNP that may be easily acquired has been studied little. Methods: Ninety-nine subjects were enrolled; thirty-six obese or hypertensive with dyspnoea but no echocardiographic HF findings or raised NPs served as controls, thirteen chronic HF (CHF) patients and fifty patients with acute decompensated HF (ADHF) requiring hospital admission. Electrocardiogram, echocardiogram, 6 min walking distance (6MWD), blood and saliva samples, were acquired in all participants. Results: Serum NT-proBNP ranged from 60-9000 pg/mL and saliva NT-proBNP from 0.64-93.32 pg/mL. Serum NT-proBNP was significantly higher in ADHF compared to CHF (p = 0.007) and in CHF compared to controls (p < 0.05). There was no significant difference in saliva values between ADHF and CHF, or between CHF and controls. Saliva and serum levels were positively associated only in ADHF patients (R = 0.352, p = 0.012). Serum NT-proBNP was positively associated with NYHA class (R = 0.506, p < 0.001) and inversely with 6MWD (R = -0.401, p = 0.004) in ADHF. Saliva NT-proBNP only correlated with age in ADHF patients. Conclusions: In the current study, saliva NT-proBNP correlated with serum values in ADHF patients, but could not discriminate between HF and other causes of dyspnoea. Further research is needed to explore the value of saliva NT-proBNP.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Prognosis of decompensated heart failure: role of NT-proBNP
    Ferreira, S.
    Almeida, R.
    Guerrero, H.
    Ferreira, S. U.
    Fonseca, L.
    Azevedo, A.
    Ferreira, A.
    Bettencourt, P.
    EUROPEAN HEART JOURNAL, 2005, 26 : 71 - 71
  • [2] The potential role of NT-proBNP in screening for and predicting prognosis in heart failure: a survival analysis
    Taylor, C. J.
    Roalfe, A. K.
    Iles, R.
    Hobbs, F. D. R.
    BMJ OPEN, 2014, 4 (04):
  • [3] NT-proBNP: An independent predictor of heart failure
    Bibbins-Domingo, K
    Ali, S
    Wu, AH
    Whooley, MA
    CIRCULATION, 2006, 113 (08) : E333 - E333
  • [4] Sequential Evaluation of NT-proBNP in Heart Failure
    Armstrong, Paul W.
    Zheng, Yinggan
    Troughton, Richard W.
    Lund, Lars H.
    Zhang, Jian
    Lam, Carolyn S. P.
    Westerhout, Cynthia M.
    Blaustein, Robert O.
    Butler, Javed
    Hernandez, Adrian F.
    Roessig, Lothar
    O'Connor, Christopher M.
    Voors, Adrian A.
    Ezekowitz, Justin A.
    JACC-HEART FAILURE, 2022, 10 (09) : 677 - 688
  • [5] NT-PROBNP GUIDED HEART FAILURE THERAPY
    Januzzi, James L., Jr.
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2011, 49 : S174 - S174
  • [6] Optimizing patient selection in heart failure trials: the role of NT-proBNP
    Savarese, G.
    Orsini, N.
    Hage, C.
    Vedin, O.
    Cosentino, F.
    Rosano, G.
    Dahlstrom, U.
    Lund, L. H.
    EUROPEAN HEART JOURNAL, 2018, 39 : 223 - 223
  • [7] Predictors of NT-proBNP response in primary care patients with heart failure and NT-proBNP guided therapy
    Erntell, H.
    Swedberg, K.
    Jorgensen, L.
    Dahlstrom, U.
    Persson, H.
    EUROPEAN JOURNAL OF HEART FAILURE, 2013, 12 : S31 - S31
  • [8] The importance of serial NT-proBNP testing in heart failure
    Hernandez, AF
    Stebbins, A
    Troughton, RW
    Hartmann, F
    Bettencourt, P
    Bayes-Genis, A
    Hasselblad, V
    Newby, LK
    CIRCULATION, 2005, 112 (17) : U405 - U405
  • [9] Barostim, NT-proBNP, And Clinical Outcomes In Heart Failure
    Abraham, Joseph d.
    Abraham, William t.
    Lindenfeld, Joann
    Weaver, Fred a.
    Zannad, Faiez
    Wilks, Seth
    Rogers, Tyson
    Zile, Michael r.
    JOURNAL OF CARDIAC FAILURE, 2025, 31 (01)
  • [10] NT-proBNP in heart failure: therapy decisions and monitoring
    Richards, M
    Troughton, RW
    EUROPEAN JOURNAL OF HEART FAILURE, 2004, 6 (03) : 351 - 354